Evaluation of Toll-Like Receptors 2/3/4/9 Gene Polymorphisms in Cervical Cancer Evolution

详细信息    查看全文

• 作者：Sabrina Zidi ; Ikram Sghaier ; Ezzedine Gazouani…
• 关键词：Toll ; like receptor ; Cervical cancer ; Gene polymorphism ; FIGO stage
• 刊名：Pathology & Oncology Research
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：22
• 期：2
• 页码：323-330
• 全文大小：271 KB
• 参考文献：1.Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRef PubMed
  2.Bernard HU, Burk RD, Chen Z, vanDoorslaer K, Hausen H, De Villiers EM (2010) Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:70–79CrossRef PubMed PubMedCentral
  3.Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, et al. (2002) Incidence, prevalence, and clearance of typespecific human papillomavirus infections: the Young Women’s Health Study. J Infect Dis 186:462–469CrossRef PubMed
  4.Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2:675–680CrossRef PubMed
  5.DeCarlo CA, Rosa B, Jackson R, Niccoli S, Escott NG, Zehbe I (2011) Toll-like receptor transcriptome in the HPV-positive cervical cancer microenvironment clinical. Dev Immunol 2012:785–825
  6.Pandey S, Mittal B, Srivastava M, Singh S, Srivastava K, Lal P, Mittal RD (2011) Evaluation of toll-like receptors 3 (c 1377C/T) and 9 (G2848A) gene polymorphisms in cervical cancer susceptibility. Mol Biol Rep 38:4715–4721CrossRef PubMed
  7.Pandey S, Mittal RD, Srivastava M, Srivastava K, Singh S, Srivastava S, Mittal B (2009) Impact of toll-like receptors [TLR] 2 (−196 to −174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women. Gynecol Oncol 114:501–505CrossRef PubMed
  8.Roszak A, Lianeri M, Sowin’ska A, Jagodzin’ski PP (2012) Involvement of toll-like receptor 9 polymorphism in cervical cancer development. Mol Biol Rep 39:8425–8430CrossRef PubMed PubMedCentral
  9.Chen X, Wang S, Liu L, Chen Z, Qiang F, Kan Y, Shen Y, Wu J, Shen H, Hu Z (2012) A genetic variant in the promoter region of toll-like receptor 9 and cervical cancer susceptibility. DNA Cell Biol 31:766–771CrossRef PubMed
  10.Shepperd JH (1995) FIGO staging of gynecologic cancers; cervical and vulva. Int J Gynecol Cancer 5:319–323
  11.Fajardo-Dolci G, Solorio-Abreu J, Romero-Álvarez JC, Zavaleta-Villa B, Cerezo-Camacho O, Jiménez-Lucio R, Olivo-Díaz A (2006) DQA1 and DQB1 association and nasal polyposis. Otolaryngol Head Neck Surg 135:243–247CrossRef PubMed
  12.Lorenz E, Frees KL, Schwartz DA (2001) Determination of the TLR4 genotype using allele-specific PCR. Biotechniques 31:22–24PubMed
  13.Tahara T, Arisawa T, Wang F, Shibata T, Nakamura M, Sakata M, Hirata I, Nakano H (2007) Toll-like receptor 2–196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci 98:1790–1794CrossRef PubMed
  14.Cheng PL, Eng HL, Chou MH, Chou MH, You HL, Lin TM (2007) Genetic polymorphisms of viral infection-associated toll-like receptors in Chinese population. Transl Res 150:311–318CrossRef PubMed
  15.De Giovine FS, Camp NJ, Cox A, Chaudhary AG, Sorrell JA, Crane A, Duff GW (2000) Detection and population analysis of IL-1 and TNF gene polymorphisms. In: Balkwill F (ed) Cytokine molecular biology. Oxford University, Oxford, pp. 21–46
  16.Zidi S, Verdi H, Yilmaz-Yalcin Y, Yazici AC, Gazouani E, Mezlini A, Atac FB, Yacoubi-Loueslati B (2014) Involvement of toll-like receptors in cervical cancer susceptibility among Tunisian women. Bull Cancer 101:E31–EE5PubMed
  17.Etem EO, Elyas H, Ozgocmen S, Yıldırım A, Godekmerdan A (2010) The investigation of toll-like receptor 3, 9 and 10 gene polymorphisms in Turkish rheumatoid arthritis patients. Rheumatol Int 31:1369–1374CrossRef PubMed
  18.He JF, Jia WH, Fan Q, Zhou XX, Qin HD, Shugart YY, Zeng YX (2007) Genetic polymorphisms of TLR3 are associated with nasopharyngeal carcinoma risk in Cantonese population. Bio Med Cent Cancer 7:194
  19.Salomé GR, Laura M, Lucía G, Luis OG, José MC, Maria LL, José MGQ, Francisco JV (2010) Study of TLR3, TLR4 and TLR9 in breast carcinomas and their associationwithmetastasis. BMC Cancer 10:665CrossRef
  20.El-Omar EM, Ng MT, Hold GL (2008) Polymorphisms in toll-like receptor genes and risk of cancer. Oncogene 27:244–252CrossRef PubMed
  21.Jing JJ, Li M, Yuan Y (2012) Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in cancer: a meta-analysis. Gene 499:237–242CrossRef PubMed
  22.Noguchi E, Nishimura F, Fukai H, et al. (2004) An association study of asthma and total serum immunoglobin E levels for toll-like receptor polymorphisms in a Japanese population. Clin Exp Allergy 34:177–183. doi:10.​1111/​j.​1365-2222.​2004.​01839.​x CrossRef PubMed
  23.Berghofer B, Frommer T, Konig IR, et al. (2005) Common human toll-like receptor 9 polymorphisms and haplotypes: association with atopy and functional relevance. Clin Exp Allergy 35:1147–1154. doi:10.​1111/​j.​1365-2222.​2005.​02325.​x CrossRef PubMed
  24.DeCarlo CA, Rosa B, Jackson R, Niccoli S, Escott NG, Zehbe I (2012) Toll-like receptor transcriptome in the hpv-positive cervical cancer microenvironment. Clin Dev Immunol 2012(ID 785825):9 Hindawi Publishing Corporation
  
• 作者单位：Sabrina Zidi (1)
  Ikram Sghaier (1)
  Ezzedine Gazouani (2)
  Amel Mezlini (3)
  Besma Yacoubi-Loueslati (1)
  
  1. Faculty of Sciences of Tunis, Laboratory of Micro-Organisms and Active Biomolecules, El Manar University, 2092 El MANAR I, 1092, Tunis, Tunisia
  2. Laboratory of Immunology, Military Hospital of Tunis, Tunis, Tunisia
  3. Salah Azeiz Oncology Institute, Tunis, Tunisia
  
• 刊物主题：Cancer Research; Oncology; Pathology; Immunology; Biomedicine general;
• 出版者：Springer Netherlands
• ISSN：1532-2807

文摘

Accumulative epidemiological evidence suggests that polymorphisms of Toll-like receptors signaling pathway elucidated the cellular and molecular mechanisms of human diseases whose gaining a primordial importance. The aim of our study is to identify the role of TLR 2 (−196 to −174 del), TLR 3 (1377 C>T), TLR 4 (Asp299Gly) and TLR 9 (G2848A) gene polymorphisms with the evolution of cervical cancer in Tunisian women. Blood samples were collected from histopathologically confirmed patients with cervical cancer and unrelated healthy female controls of similar ethnicity. Genotyping of the analyzed polymorphisms were done using Polymerase Chain Reaction and Restriction Fragment Length Polymorphism. For the TLR 2, Ins/Ins genotype is a protector factor [p = 0.006; OR: 0.35(0.16–0.73)] and the dominant genotype of TLR 3 increased the risk of CC in stage (III+IV); C/C versuss C/T [p = 0.033; OR: 2.03(1.00–4.13)] and C/C versus C/T+T/T [p = 0.036; OR: 1.93(1.00–3.74)]. For TLR 4, the dominant genotype Asp/Asp is implicated in the occurrence of CC in stage (I+II) [p = 0.000; OR: 4.55(1.58–13.06)], [p = 0.001; OR: 3.49(1.44–8.45)] and in stage (III+IV) [p = 0.038; OR: 3.77(0.87–16.29)], [p = 0.007; OR: 5.21(1.65–16.46)] and the major allele Asp is a risk factor for the development of tumor in stage (I+II). The TLR2 Ins/Del genotype is associated with tumor evolution to stage (III+IV) [p = 0.003; OR: 3.00 (1.22–7.35)] and the genotypes Gly/Gly and Asp/Gly+Gly/Gly and Gly allele of TLR 4 are implicated in tumor evolution to the advanced stages. Further, TLR 2, TLR 3, TLR 4 and TLR 9 gene polymorphisms are implicated in the modulation of CC risk due to tobacco usage and statue of menopause among cases. Our study suggests a relationship between the incidence of the TLR2, TLR 3, TLR 4 and TLR9 mutations and the clinical progression of CC according to the FIGO classification. However, future studies with different demographic and clinical characteristics in ethnically diverse populations may provide a more comprehensive involvement of innate immunity in cervical cancer etiology in women worldwide.